The present invention relates to compositions and methods for manufacturing an adjuvant comprising an aminoalkyl glucosaminide phosphate compound or glucopyranosyl lipid adjuvant using a microfluidic device and to related aspects.

The present invention provides an mRNA molecule encoding at least one KRAS variant peptide. Further, the invention provides a pharmaceutical composition and kit comprising the mRNA molecule. The mRNA molecule, pharmaceutical composition and kit are useful for treating cancer.

The present invention provides an mRNA molecule encoding at least one KRAS variant peptide. Further, the invention provides a pharmaceutical composition and kit comprising the mRNA molecule. The mRNA molecule, pharmaceutical composition and kit are useful for treating cancer.

The disclosure relates to dry powder compositions of (a) a plant-based cannabidiol (pCBD) composition, or (b) a plant-based tetrahydrocannabinol composition (pTHC); or (c) a synthetic cannabidiol composition (sCBD), or (d) a synthetic tetrahydrocannabinol composition (sTHC), or (e) a plant-based cannabidiol (pCBD) composition in combination with a plant-based tetrahydrocannabinol composition (pTHC), or (f) a synthetic cannabidiol composition (sCBD) in combination with a synthetic tetrahydrocannabinol composition (sTHC) and their delivery to the airway of a subject using a dry powder inhaler.

The disclosure relates to dry powder compositions of (a) a plant-based cannabidiol (pCBD) composition, or (b) a plant-based tetrahydrocannabinol composition (pTHC); or (c) a synthetic cannabidiol composition (sCBD), or (d) a synthetic tetrahydrocannabinol composition (sTHC), or (e) a plant-based cannabidiol (pCBD) composition in combination with a plant-based tetrahydrocannabinol composition (pTHC), or (f) a synthetic cannabidiol composition (sCBD) in combination with a synthetic tetrahydrocannabinol composition (sTHC) and their delivery to the airway of a subject using a dry powder inhaler.

The present disclosure relates to improvements in the selection and formulation of PBAE polymers using a design of experiment approach, in which statistical methods are used to limit possible experimental conditions. The present disclosure relates to improved PBAE polymers and formulations.

The present disclosure relates to improvements in the selection and formulation of PBAE polymers using a design of experiment approach, in which statistical methods are used to limit possible experimental conditions. The present disclosure relates to improved PBAE polymers and formulations.

The disclosure features isolated polynucleotides, such as mRNAs, encoding a polypeptide that disrupts immune cell activity, such as T cell or B cell activity, including mRNAs comprising one or more modified nucleobase. The immune cell disruptor polynucleotides encode a polypeptide that comprises a first domain that mediates association of the polypeptide with an immune cell component and a second domain that mediates inhibition of immune cell activity when the polypeptide is expressed in the immune cell. The disclosure also features methods of using the same, for example, for inhibiting immune responses when administered to a subject, such as to inhibit autoimmune reactions.

The disclosure features isolated polynucleotides, such as mRNAs, encoding a polypeptide that disrupts immune cell activity, such as T cell or B cell activity, including mRNAs comprising one or more modified nucleobase. The immune cell disruptor polynucleotides encode a polypeptide that comprises a first domain that mediates association of the polypeptide with an immune cell component and a second domain that mediates inhibition of immune cell activity when the polypeptide is expressed in the immune cell. The disclosure also features methods of using the same, for example, for inhibiting immune responses when administered to a subject, such as to inhibit autoimmune reactions.

Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.